In our prospective study, we found decreased in vivo activation of ficolin-3-mediated lectin and alternative pathways during bacterial infections in patients with type 2 diabetes in comparison with non-diabetic subjects. This evidence concerns the gene FCN3 and type 2 diabetes mellitus.